HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor

被引：44
|
作者：
Lisziewicz, J
Jessen, H
Finzi, D
Siliciano, RF
Lori, F [1 ]
机构：
[1] Georgetown Univ, RIGHT, Washington, DC 20007 USA
[2] Policlin San Matteo, IRCCS, RIGHT, I-27100 Pavia, Italy
[3] Jessen Praxis, Berlin, Germany
[4] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA
来源：
LANCET | 1998年 / 352卷 / 9123期
关键词：
D O I：
10.1016/S0140-6736(98)24029-3
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：199 / 200
页数：2
相关论文
共 50 条
  • [21] The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir
    Kempf, DJ
    Rode, RA
    Xu, Y
    Sun, E
    Heath-Chiozzi, ME
    Valdes, J
    Japour, AJ
    Danner, S
    Boucher, C
    Molla, A
    Leonard, JM
    AIDS, 1998, 12 (05) : F9 - F14
  • [22] Inhibition of HIV-1 replication by a peptide dimerization inhibitor of HIV-1 protease
    Davis, David A.
    Brown, Cara A.
    Singer, Kathleen E.
    Wang, Victoria
    Kaufman, Joshua
    Stahl, Stephen J.
    Wingfield, Paul
    Maeda, Kenji
    Harada, Shigeyoshi
    Yoshimura, Kazuhisa
    Kosalaraksa, Pope
    Mitsuya, Hiroaki
    Yarchoan, Robert
    ANTIVIRAL RESEARCH, 2006, 72 (02) : 89 - 99
  • [23] Hydroxyurea plus didanosine (ddI) in HIV-1 positive, asymptomatic patients. A toxicity analysis
    Maserati, R
    Seminari, E
    Lori, F
    Foli, A
    Lisziewicz, J
    AIDS, 1998, 12 : S40 - S40
  • [24] HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat
    Fun, Axel
    van Maarseveen, Noortje M.
    Pokorna, Jana
    Maas, Renee E. M.
    Schipper, Pauline J.
    Konvalinka, Jan
    Nijhuis, Monique
    RETROVIROLOGY, 2011, 8
  • [25] HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat
    Axel Fun
    Noortje M van Maarseveen
    Jana Pokorná
    Renée EM Maas
    Pauline J Schipper
    Jan Konvalinka
    Monique Nijhuis
    Retrovirology, 8
  • [26] Ritonavir-boosted protease inhibitor monotherapy for the treatment of HIV-1 infection
    Sahali, Sabrinel
    Chaix, Marie-Laure
    Delfraissy, Jean-Francois
    Ghosn, Jade
    AIDS REVIEWS, 2008, 10 (01) : 4 - 14
  • [27] Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV
    Ghosh, Arun K.
    Dawson, Zachary L.
    Mitsuya, Hiroaki
    BIOORGANIC & MEDICINAL CHEMISTRY, 2007, 15 (24) : 7576 - 7580
  • [28] HIV-1 Protease Mutations and Protease Inhibitor Cross-Resistance
    Rhee, Soo-Yon
    Taylor, Jonathan
    Fessel, W. Jeffrey
    Kaufman, David
    Towner, William
    Troia, Paolo
    Ruane, Peter
    Hellinger, James
    Shirvani, Vivian
    Zolopa, Andrew
    Shafer, Robert W.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (10) : 4253 - 4261
  • [29] Atazanavir: A novel azapeptide inhibitor of HIV-1 protease
    Wang, F
    Ross, J
    FORMULARY, 2003, 38 (12) : 691 - +
  • [30] Development of Sharkavir: A Hypothetical Inhibitor for HIV-1 Protease
    Hunt, Matthew
    Abbas, Feza
    Abbas, Lyla
    Ghali, Mina
    Ghali, Helana
    Chabbra, Alesa
    Lavin, Emily
    Sikora, Arthur
    FASEB JOURNAL, 2020, 34
12345